摘要
c-Met为一种由原癌基因MET编码的跨膜受体酪氨酸激酶,是肝细胞生长因子的受体,与多种癌症的不良预后有关。近年来,c-Met抑制剂作为一种对抗癌症的有效策略备受关注。结合汤森路透数据库资源——Thomson Reuters Integrity和Cortellis for Competitive Intelligence,对c-Met在疾病中的作用、相关药物研究进展、适应证、研发机构、交易、专利、文献等情报进行了数据层面的分析。
c-Met is a transmembrane receptor tyrosine kinase that is encoded by MET proto-oncogene. It serves as a receptor for hepatocyte growth factor (HGF). The abnormal level of c-Met is correlated with poor prognosis in a number of cancers. As an effective therapeutic strategy, the c-Met inhibitors have been paid much attention recently. The intelligence of c-Met, including role in diseases, research progress of related drugs, indications, originators, deals, patents and references, have been analyzed by Thomson Reuters Integrity and Cortellis for Competitive Intelligence in this paper.
出处
《药学进展》
CAS
2014年第5期392-400,共9页
Progress in Pharmaceutical Sciences